ABSTRACT In the United States (US), the highest incidence of invasive meningococcal disease (IMD) is among infants aged ≤ 1 year (y). While most IMD cases in US infants are caused by meningococcal serogroup B (MenB), there is no MenB vaccine approved or recommended for US children < 10 y. This study sought to understan...
O. Herrera-Restrepo, Vasudha Gupta, Sophie Jacobovitz et al.· Human Vaccines & Immunothera...· 0 citations
BACKGROUND/OBJECTIVE
Although uncommon, invasive meningococcal disease (IMD) is a serious and life-threatening illness. In the United States (US), incidence is highest among infants aged <1 year, but research characterizing pediatric IMD burden is limited. This study aimed to evaluate health outcomes and economic burde...
O. Herrera-Restrepo, Elizabeth Packnett, Megan K. Richards et al.· PharmacoEconomics - Open· 0 citations
Evidence of high 4CMenB VE against serogroup B-IMD in fully vaccinated infants and children in fully vaccinated infants and children across different geographic regions is provided.
Pavo Marijic, Katarzyna Jamróz-Dolińska, W. Margas et al.· npj Vaccines· 0 citations
BACKGROUND
Invasive meningococcal disease (IMD) is a vaccine-preventable, serious disease. In 2023-2024, the United States (US) Advisory Committee on Immunization Practices (ACIP) proposed revisions to the adolescent meningococcal vaccine schedule. This survey aimed to understand healthcare professionals' (HCPs') persp...
O. Herrera-Restrepo, Laurie Batchelder, T. Pinto et al.· Expert Review of Vaccines· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
